Esperion Therapeutics Inc (ESPR) Upgraded by Credit Suisse Group AG to Neutral

Esperion Therapeutics Inc (NDAQ:ESPR) was upgraded by analysts at Credit Suisse Group AG from an “underperform” rating to a “neutral” rating in a research report issued on Monday, reports.

A number of other equities research analysts also recently weighed in on ESPR. Royal Bank of Canada upped their target price on Esperion Therapeutics from $20.00 to $30.00 and gave the stock a “sector perform” rating in a research report on Thursday, February 23rd. Citigroup Inc upgraded Esperion Therapeutics from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 28th.

Esperion Therapeutics (NDAQ:ESPR) traded up 25.06% during midday trading on Monday, hitting $37.08. The stock had a trading volume of 25,611,353 shares. The firm has a 50 day moving average price of $23.80 and a 200 day moving average price of $15.00. The stock’s market cap is $836.34 million. Esperion Therapeutics has a one year low of $9.40 and a one year high of $37.47.

var userip;Your IP Address: document.write(userip);

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Stock Target Prices

Receive News & Ratings for Esperion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2017 Mideast Time.